1. Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. (February 2017) Authors: Hong, D.S.; Dowlati, A.; Burris, H.A.; Lee, J.J.; Brose, M.S.; Farago, A.F.; Bauer, T.M.; Taylor, M.; Shaw, A.T.; Smith, S.; Nanda, N.; Cruikshank, S.; Cox, M.C.; Doebele, R.C. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO4 Toxicity outcomes from conformal prone breast radiotherapy and a dosimetric comparison with hybrid IMRT prone radiotherapy. (April 2018) Authors: Byrne, K.; Ambrose, L.; Bromley, R.; Cruikshank, S.; Guo, L.; Morgia, M.; Lamoury, G. Journal: Breast Issue: Volume 38(2018) Page Start: 194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗